Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types

Retrieved on: 2021-05-17 12:00:00

Tags for this article:

Chemical compounds

Organic compounds

Hepatocellular carcinoma

Pembrolizumab

Eisai Inc.

Click the tags to see associated articles and topics

Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types. View article details on HISWAI: https://www.prnewswire.com/news-releases/eisai-data-at-asco-2021-highlight-breadth-of-oncology-portfolio-across-various-tumor-types-301292077.html

Excerpt

Key analyses on the lenvatinib plus pembrolizumab combination include a poster on the primary analysis of the health-related quality of life (HRQoL) ...

Article found on: www.prnewswire.com

View Original Article